2. Academic Validation
  3. Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development

Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development

  • Bioorg Med Chem Lett. 2012 Nov 15;22(22):6974-9. doi: 10.1016/j.bmcl.2012.08.100.
Patrick Raboisson 1,  Anna Breitholtz-Emanuelsson,  Henrik Dahllöf,  Louise Edwards,  William L Heaton,  Methvin Isaac,  Keith Jarvie,  Annika Kers,  Alexander B E Minidis,  Anna Nordmark,  Susan M Sheehan,  Abdelmalik Slassi,  Peter Ström,  Ylva Terelius,  David Wensbo,  Julie M Wilson,  Tao Xin,  Donald A McLeod
Affiliations

Affiliation

  • 1 AstraZeneca R&D, Södertälje S-15185, Sweden. patrick.raboisson.1@gmail.com
PMID: 23046966 DOI: 10.1016/j.bmcl.2012.08.100
Abstract

AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z